Your browser is no longer supported. Please, upgrade your browser.
Better Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own2.40% Shs Outstand7.56M Perf Week-0.55%
Market Cap165.83M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.27M Perf Month-34.28%
Income- PEG- EPS next Q- Inst Own16.10% Short Float6.28% Perf Quarter-27.61%
Sales- P/S- EPS this Y- Inst Trans-18.22% Short Ratio0.21 Perf Half Y-27.10%
Book/sh7.38 P/B0.98 EPS next Y- ROA- Target Price21.00 Perf Year-
Cash/sh0.01 P/C552.77 EPS next 5Y- ROE- 52W Range6.36 - 29.40 Perf YTD-27.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-75.48% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low13.45% ATR1.93
Employees- Current Ratio3.70 Sales Q/Q- Oper. Margin- RSI (14)40.16 Volatility19.97% 22.52%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.28 Prev Close7.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.18M Price7.21
Recom- SMA20-25.38% SMA50-26.92% SMA200-27.24% Volume612,882 Change-6.12%
Nov-24-21Initiated Chardan Capital Markets Buy $17
Nov-10-21Initiated Cowen Outperform
Nov-18-21 08:00AM  
Nov-11-21 08:00AM  
Nov-04-21 08:00AM  
Nov-02-21 08:00AM  
Better Therapeutics, Inc. develops prescription digital therapeutics that delivers behavioral therapy, and creates feedback mechanisms using remotely monitored and patient-generated data. Its products include Nutritional Cognitive Behavioral Therapy (Nutritional CBT), behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It also manufactures therapeutic medicines, such as BTA001, BTA002, BTA003, BTA004, and BTA005 for cardiometabolic diseases. The company was incorporated in 2015 and is based in San Francisco, California.